#CAMX

Camurus announces FDA acceptance of NDA resubmission for Oclaiz™ for the treatment of acromegaly PDUFA target action date set to 10 June 2026. LUND, Sweden, Jan. 9, 2026/ PRNewswire/-- Camurus today announced that the U.S. Food and Drug Administration has accepted for review the company's resubmission of the New Drug Application for Oclaiz™, octreotide extended-release injection, for the treatment of patients with acromegaly. The product received marketing...

2 months ago

#CAMX Camurus announces FDA acceptance of NDA resubmission for Oclaiz™ for the treatment of acromegaly

www.stocktitan.net/news/CAMX/camurus-announ...

0 0 0 0

2 months ago

#finanstwitter #aktier
15 största, 1 januari 2026, i storleksordning:
Sobi #SOBI
Investor #INVE
Plejd #PLEJD
Camurus #CAMX
Autoliv #ALIV
FlatexDEGIRO AG #FTK
Bonesupport #BONEX
NKT #NKT
Shelly Group Plc #SLYG
XTB #XTB
VEF #VEFAB
Essity #ESSITY
Elekta #EKTA
Bure #BURE
Ascelia Pharma #ACE

11 0 0 0

3 months ago

#finanstwitter #aktier
15 största, 1 december 2025, i storleksordning:
Sobi #SOBI
Plejd #PLEJD
Investor #INVE
Camurus #CAMX
NKT #NKT
Autoliv #ALIV
Bonesupport #BONEX
FlatexDEGIRO AG #FTKd
Shelly Group Plc #SLYGd
VEF #VEFAB
XTB #XTB
Essity #ESSITY
Elekta #EKTA
Bure #BURE
Ascelia Pharma #ACE

5 0 0 0

Camurus reports positive topline results for CAM2056, semaglutide monthly depot Camurus (NASDAQ: CAMX) reported positive topline Phase 1b results for CAM2056, a monthly FluidCrystal semaglutide depot, in 80 participants with overweight or obesity on Nov 10, 2025. CAM2056 delivered dose-dependent reductions in body weight, A1c and fasting glucose that were comparable to or exceeded weekly semaglutide to Day 85.Key data: weight -9.3% for CAM2056 10 mg vs -5.2% for weekly semaglutide (treatment diff -4.1%, p=0.008); A1c -0.44% for CAM2056 with treatment diff -0.32% (p<0.001). Safety was generally consistent with weekly semaglutide, though the highest initiation cohort had more frequent/severe events. A Phase 2b study is planned.

4 months ago

#CAMX Camurus reports positive topline results for CAM2056, semaglutide monthly depot

www.stocktitan.net/news/CAMX/camurus-report...

0 0 0 0

4 months ago

#finanstwitter #aktier
Camurus #CAMX
Ny kvartalsrapport!

2 0 0 0

4 months ago

#finanstwitter #aktier
15 största, 1 november 2025, i storleksordning:
Plejd #PLEJD
Sobi #SOBI
Investor #INVE
Camurus #CAMX
Bonesupport #BONEX
NKT #NKT
FlatexDEGIRO AG #FTKd
VEF #VEFAB
ALK-Abelló #ALK
Autoliv #ALIV #ALV
Shelly Group Plc #SFLYG
Essity #ESSITY
Elekta #EKTA
Orion #ORNBV
Bure #BURE

5 0 0 0

@axelplastics.bsky.social

5 months ago

#finanstwitter
15 största, 1 oktober 2025, i storleksordning:
Plejd #PLEJD
Camurus #CAMX
Investor #INVE
Bonesupport #BONEX
NKT #NKT
ALK-Abelló #ALK
FlatexDEGIRO AG #FTKd
Autoliv #ALIV #ALV
Shelly Group Plc #SFLYG
VEF #VEFAB
Sobi #SOBI
Essity #ESSITY
Elekta #EKTA
Orion #ORNBV
Dynavox #DYVOX

6 0 0 0

AXEL Plastics

6 months ago

CAMX 2025 starts tomorrow! Visit Booth F22 to discover the latest in advanced mold release solutions and connect with AXEL’s technical experts in person. Don’t miss your chance to tackle your toughest molding challenges—let’s shape the future of composites together.

#moldrelease #composites #CAMX

1 0 0 0

@pinpoint-estimates.bsky.social

6 months ago

#finanstwitter
15 största, 1 september 2025, i storleksordning:
Plejd #PLEJD
Camurus #CAMX
Bonesupport #BONEX
Investor #INVE
NKT #NKT
Shelly Group Plc #SFLYG
FlatexDEGIRO AG #FTKd
VEF #VEFAB
Autoliv #ALIV #ALV
Dynavox #DYVOX
Sobi #SOBI
Essity #ESSITY
ALK-Abelló #ALK
Beijer Ref #BEIJ
Elekta #EKTA

15 0 4 0

Pinpoint Estimates

7 months ago

#CAMX rapporterar klart över förväntan.

Man visar tillväxt om 52% på omsättning och ett klart förbättrat EBIT som uppgår till 292,1 MSEK (82,6).

3 0 1 0

7 months ago

Såg bra ut det här kvartalet, Camurus #CAMX. Kanske var förra bara ett hack i kurvan. #finanstwitter

2 0 1 0

8 months ago

#finanstwitter #aktier
15 största, 1 juli 2025, i storleksordning:
Plejd #PLEJD
Camurus #CAMX
Investor #INVE
Bonesupport #BONEX
Tomra #TOM
Shelly Group Plc #SFLYG
Autoliv #ALIV #ALV
NKT #NKT
Essity #ESSITY
FlatexDEGIRO AG #FTKd
Dynavox #DYVOX
Elekta #EKTA
Bure #BURE
VEF #VEFAB
Stille #STIL

14 0 1 0

Camurus' Oczyesa® receives marketing authorization for treatment of acromegaly in the EU First subcutaneous, once-monthly octreotide for treatment of acromegaly For convenient self-administration with a pre-filled autoinjector pen. LUND, Sweden, July 1, 2025/ PRNewswire/-- Camurus today announced that the European Commission has granted Oczyesa ®, octreotide subcutaneous depot, marketing authorization* for the maintenance treatment in...

8 months ago

#CAMX Camurus' Oczyesa® receives marketing authorization for treatment of acromegaly in the EU

www.stocktitan.net/news/CAMX/camurus-oczyes...

0 0 0 0

Camurus' POSITANO study shows treatment effects with CAM2029 in polycystic liver disease patients Camurus announced positive topline results from its POSITANO Phase 2b study evaluating CAM2029 for polycystic liver disease (PLD). The study met its primary endpoint, showing a 4.3% reduction in height-adjusted liver volume and 8.7% reduction in liver cyst volume compared to placebo at week 53. The trial involved 71 participants randomized across two CAM2029 dosing regimens and placebo. CAM2029, which has received Orphan Drug Designation in both US and EU, demonstrated good tolerability with no unexpected safety concerns. Common side effects included diarrhea, gastrointestinal disturbances, and injection site reactions. PLD, affecting approximately 37,000 people in the US and EU, currently has no approved treatments. Based on these results, Camurus plans to discuss a Phase 3 study design with regulatory authorities.

8 months ago

#CAMX Camurus' POSITANO study shows treatment effects with CAM2029 in polycystic liver disease patients

www.stocktitan.net/news/CAMX/camurus-posita...

0 0 0 0

Eli Lilly Bets $870M on Camurus FluidCrystal Tech to Transform Diabetes and Obesity Treatment Novel FluidCrystal technology to power next-gen incretin therapies. Partnership includes $290M upfront and milestone payments. See development pipeline details.

9 months ago

#CAMX Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins

www.stocktitan.net/news/CAMX/camurus-and-li...

1 0 0 0

9 months ago

#finanstwitter
15 största, 1 juni 2025, i storleksordning:
Plejd #PLEJD
Camurus #CAMX
Investor #INVE
Bonesupport #BONEX
NKT #NKT
Essity #ESSITY
Tomra #TOM
FlatexDEGIRO AG #FTKd
Shelly Group Plc #SFLYG
Elekta #EKTA
Autoliv #ALIV #ALV
Dynavox #DYVOX
Bure #BURE
VEF #VEFAB
Ossdsign #OSSD

9 0 2 0

10 months ago

Pressmeddelandet kom fredag förra veckan. Tyckte det var konstigt att den inte reagerade alls då. Kan vara något annat också, kanske siffror från någon konkurrent i USA. #CAMX

1 0 1 0

10 months ago

#finanstwitter #aktier
15 största, 1 Maj 2025, i storleksordning:
Plejd #PLEJD
Bonesupport #BONEX
Camurus #CAMX
Investor #INVE
Essity #ESSITY
Bure #BURE
FlatexDEGIRO AG #FTKd
Elekta #EKTA
Novo Nordisk #NOVO
Autoliv #ALIV #ALV
VEF #VEFAB
Dynavox #DYVOX
Ossdsign #OSSD
NKT #NKT
Tomra #TOM

6 0 0 0

@oakbeartravel.bsky.social

11 months ago

#finanstwitter #aktier
15 största, 1 April 2025, i storleksordning:
Investor #INVE
Plejd #PLEJD
Bonesupport #BONEX
Camurus #CAMX
Essity #ESSITY
Elekta #EKTA
Bure #BURE
Sobi #SOBI
FlatexDEGIRO AG #FTKd
Autoliv #ALIV #ALV
VEF #VEFAB
Flat Capital #FLAT
Acast #ACAST
Tomra #TOM
NKT #NKT

8 0 0 0

Oakbear

1 year ago

Köpläge i #Novo #Sobi #Camx och #Bure

0 0 0 0

A Naturalistic Study of Individuals Involved in the Justice System Who Experienced Both Formulations of Extended-release Buprenorphine - PubMed Patients may prefer Brixadi to Sublocade because of injection site pain/discomfort. This could be mitigated with topical or subcutaneous anesthetics. Findings are mixed with respect to the effect of t...

1 year ago

#finanstwitter #aktier
15 största, 1 Mars 2025, i storleksordning:
Bonesupport #BONEX
Camurus #CAMX
Investor #INVE
Plejd #PLEJD
Elekta #EKTA
Essity #ESSITY
Sobi #SOBI
Bure #BURE
Autoliv #ALIV #ALV
FlatexDEGIRO AG #FTKd
Novo Nordisk #NOVO
VEF #VEFAB
Acast #ACAST
Flat Capital #FLAT
Tomra #TOM

10 0 1 0

Nordic GARP

@nordicgarp.bsky.social

1 year ago

Superintressant artikel publicerad i Journal of Addiction Medicine där Brixadi jämförs med Sublocade bland fångar i USA.

Results: In general, most participants preferred Brixadi, and most found Sublocade to cause more injection site pain/discomfort.

pubmed.ncbi.nlm.nih.gov/39888715/

#CAMX

2 0 1 0